Combination of mTOR Inhibitors Augments Potency while Activating PI3K Signaling in Pituitary Tumors

Publisher： Karger

E-ISSN： 1423-0194|103|5|592-604

ISSN： 0028-3835

Source： Neuroendocrinology, Vol.103, Iss.5, 2015-11, pp. : 592-604

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

VEGF Secretion by Neuroendocrine Tumor Cells Is Inhibited by Octreotide and by Inhibitors of the PI3K/AKT/mTOR Pathway

By  

Neuroendocrinology, Vol. 91, Iss. 3, 2010-04 ,pp. : 268-278

Karger

Access to resources Recommend Favorite

Interleukin-1β Plays a Pivotal Role via the PI3K/Akt/mTOR Signaling Pathway in the Chronicity of Mesial Temporal Lobe Epilepsy

By  

Neuroimmunomodulation, Vol. 23, Iss. 5-6, 2017-04 ,pp. : 332-344

Karger

Access to resources Recommend Favorite

Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells

By  

Neuroendocrinology, Vol. 103, Iss. 6, 2015-12 ,pp. : 724-737

Karger

Access to resources Recommend Favorite

Signaling Pathways as Specific Pharmacologic Targets for Neuroendocrine Tumor Therapy: RET, PI3K, MEK, Growth Factors, and Notch

By  

Neuroendocrinology, Vol. 97, Iss. 1, 2012-02 ,pp. : 57-66

Karger

Access to resources Recommend Favorite

Octreotide and the mTOR Inhibitor RAD001 (Everolimus) Block Proliferation and Interact with the Akt-mTOR-p70S6K Pathway in a Neuro-Endocrine Tumour Cell Line

By  

Neuroendocrinology, Vol. 87, Iss. 3, 2007-11 ,pp. : 168-181

Karger

Access to resources Recommend Favorite